MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Recursion Pharmaceuticals Inc

Fechado

SetorSaúde

5.28 -7.69

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.25

Máximo

5.32

Indicadores-chave

By Trading Economics

Rendimento

-24M

-202M

Vendas

10M

15M

Margem de lucro

-1,373.259

Funcionários

800

EBITDA

-26M

-191M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+13.64% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-313M

2B

Abertura anterior

12.97

Fecho anterior

5.28

Sentimento de Notícias

By Acuity

60%

40%

313 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de jul. de 2025, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

FCC Approves U.S. Cellular Sale to T-Mobile

11 de jul. de 2025, 17:28 UTC

Grandes Movimentos do Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 de jul. de 2025, 16:57 UTC

Ganhos

BASF Cuts Outlook on Global Economy Uncertainty

12 de jul. de 2025, 17:01 UTC

Ganhos

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12 de jul. de 2025, 14:53 UTC

Ganhos

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12 de jul. de 2025, 02:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 de jul. de 2025, 02:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 de jul. de 2025, 02:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 de jul. de 2025, 02:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 de jul. de 2025, 21:45 UTC

Conversa de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 de jul. de 2025, 19:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 de jul. de 2025, 19:45 UTC

Conversa de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 de jul. de 2025, 19:05 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 de jul. de 2025, 18:18 UTC

Conversa de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 de jul. de 2025, 17:35 UTC

Conversa de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 de jul. de 2025, 17:26 UTC

Conversa de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 de jul. de 2025, 16:53 UTC

Conversa de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 de jul. de 2025, 16:42 UTC

Ganhos

BASF Cuts Outlook on Global Economic Uncertainty

11 de jul. de 2025, 16:08 UTC

Conversa de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 de jul. de 2025, 16:05 UTC

Ganhos

BASF Will Publish Half-Year Results on July 30

11 de jul. de 2025, 16:04 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

11 de jul. de 2025, 16:04 UTC

Conversa de Mercado

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 de jul. de 2025, 16:03 UTC

Ganhos

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 de jul. de 2025, 16:02 UTC

Ganhos

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 de jul. de 2025, 16:01 UTC

Ganhos

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 de jul. de 2025, 16:00 UTC

Ganhos

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 de jul. de 2025, 15:59 UTC

Ganhos

BASF Cuts 2025 Earnings View

11 de jul. de 2025, 15:58 UTC

Ganhos

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 de jul. de 2025, 15:57 UTC

Ganhos

BASF 2Q EBIT Before Special Items EUR810M

11 de jul. de 2025, 15:54 UTC

Ganhos

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

Comparação entre Pares

Variação de preço

Recursion Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

13.64% parte superior

Previsão para 12 meses

Média 6 USD  13.64%

Máximo 8 USD

Mínimo 4 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Recursion Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

6 ratings

1

Comprar

5

Manter

0

Vender

Pontuação Técnica

By Trading Central

4.15 / 4.75Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

313 / 376 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.